Cytokinetics Inc SEC Filings

Cytokinetics, Incorporated reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten). The medicine is a cardiac myosin inhibitor intended to treat symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy in adult patients.

The company stated that a final decision from the European Commission on this marketing application is anticipated in the first quarter of 2026. It also highlighted that statements about potential approval are forward-looking and that actual outcomes may differ from these expectations.

Cytokinetics, Inc. reported an insider stock transaction by its President & CEO and Director on 12/03/2025. The filing shows the disposition of 5,930 shares of common stock at a price of $65.02 per share, recorded under transaction code F.

After this transaction, the reporting person directly beneficially owns 350,202 shares of Cytokinetics common stock. In addition, the filing notes indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.

CYTOKINETICS, INC. (CYTK) reported an insider stock sale by a director. On 11/19/2025, the director sold 5,000 shares of common stock in an open market transaction coded as a sale at a price of $64.73 per share. After this transaction, the director beneficially owns 22,933 shares of CYTOKINETICS common stock in direct ownership. The filing is signed by an attorney-in-fact on behalf of the reporting person.

Cytokinetics (CYTK) Form 4 discloses an insider stock option exercise and sale by an executive. The company’s Executive Vice President of Research & Development reported exercising stock options for 2,200 shares of common stock at a price of $10.60 per share on 11/18/2025, then selling 2,200 shares of common stock the same day at a price of $66.45 per share.

After these transactions, the executive directly beneficially owned 140,610 shares of Cytokinetics common stock and held 4,400 derivative securities (stock options) following the reported activity. The filing is made by a single reporting person and is a routine disclosure of insider equity transactions.

Cytokinetics, Inc. (CYTK) reported an equity award to its Chief Legal & Admin Officer, Mr. Hessekiel. On 11/14/2025, he received an initial new hire grant of 87,297 restricted stock units (RSUs) of common stock at a price of $0 per share, all held as direct ownership after the transaction.

The RSUs convert into common stock on a 1:1 basis as they vest. The vesting schedule is staggered over three years: 40% of the RSUs vest one year from the grant date, another 40% vest two years from the grant date, and the remaining 20% vest three years from the grant date, in each case conditioned on his continued employment with Cytokinetics.

Cytokinetics appointed Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, effective November 14, 2025. His compensation includes a $660,000 annual base salary, a target bonus equal to 50% of salary (75% tied to corporate goals and 25% to individual goals), and a $400,000 signing bonus split into two equal payments, with the initial portion subject to repayment if he resigns or is terminated for cause within one year.

As an inducement equity grant, he will receive restricted stock units with a grant date value of $5,800,000, vesting 40% on the first anniversary, 40% on the second, and 20% on the third, subject to continued service and potential acceleration under the company’s Executive Severance Plan. He will participate in Cytokinetics’ standard benefit, bonus, equity, and severance programs and has entered into the company’s standard indemnification agreement.

Cytokinetics (CYTK) filed a Form 4 reporting insider activity. On 11/11/2025, a director exercised 5,175 stock options at $9.66 per share (code M), then sold 5,175 shares at $65.08 (code S). After these transactions, the director beneficially owned 9,977 shares, held directly.

The exercised options were non-qualified options originally exercisable beginning 08/01/2016 and expiring 07/01/2026, covering 5,175 underlying common shares.

Cytokinetics (CYTK) reported Q3 2025 results marked by continued investment ahead of potential commercialization. Total revenue was $1.936 million, primarily from collaboration revenue. Operating expenses rose to $168.7 million, driving an operating loss of $166.8 million. Net loss widened to $306.2 million, reflecting a $121.2 million debt conversion expense tied to convertible notes activity.

Liquidity remained strong with cash, cash equivalents and investments of roughly $1.3 billion as of September 30, 2025. The balance sheet shows $1.958 billion in total liabilities, including $889.5 million in convertible notes, $158.7 million in term loans, and liabilities related to revenue participation agreements. Stockholders’ deficit was $(521.1) million. Year-to-date cash used in operations was $367.4 million.

The company continues late-stage development programs and notes a PDUFA target action date of December 26, 2025 for the NDA for aficamten in obstructive HCM. Common shares outstanding were 122,264,929 as of November 3, 2025.

Cytokinetics (CYTK) reported an insider transaction on a Form 4. The company’s President & CEO and Director reported a bona fide gift (Code G) of 2,000 shares of common stock on 11/05/2025 at a price of $0.

Following the transaction, the reporting person beneficially owns 356,108 shares directly, plus 2,083 shares held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held indirectly by The Brittany Blum 2003 Irrevocable Trust.